Figure 5:

Tumor growth following treatment with RF ablation and/or intravenous adjuvant liposomal chemotherapy (doxorubicin or paclitaxel). Scatterplot shows mean (and final standard deviation) tumor diameter to sacrifice at 3.0-cm diameter. Combination RF ablation and a single adjuvant therapy (paclitaxel–RF ablation, RF ablation–paclitaxel, RF ablation–doxorubicin) resulted in slower tumor growth and longer survival compared with untreated or RF ablation alone groups (P < .02). RF ablation–doxorubicin and paclitaxel-doxorubicin groups had greater survival compared with paclitaxel–RF ablation or RF ablation–paclitaxel groups. Paclitaxel–RF ablation–doxorubicin showed the greatest survival benefit, with mean end-point survival of 56.8 days ± 25.3 (P < .002, all comparisons). Graph was truncated at 50 days after treatment (similar survival is observed for the surviving animals from 60 to 90 days). Keys are the same as for Figure 4.